Psoriasis – Emerging Therapies – Cosentyx Launch Tracking Wave 3 (US)

Cosentyx (US) is a three-wave syndicated report series that specifically tracks the introduction of Novartis’s Cosentyx (secukinumab), a potent, subcutaneous IL-17 inhibitor approved for the treatment of psoriasis (PsO). This report series is based on primary research data collected at one month, six months, and one year post-commercial availability of Cosentyx. Along with awareness and sources of familiarity, the reports assess U.S. dermatologists’ trial, adoption, and use of Cosentyx, including anticipated future trends. The reports also provide information on product perceptions, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Novartis’s promotional efforts, and benchmarking against other previously launched immune agents.

Table of contents

  • Psoriasis - Emerging Therapies - Cosentyx Launch Tracking Wave 3 (US)
    • Key Findings
      • Awareness and Perceptions of Cosentyx
      • Cosentyx Trial and Use
      • Competitive Landscape and Cosentyx Promotion
    • Benchmarking Cosentyx Launch Success vs. the Competition
      • Benchmarking Cosentyx Launch Success vs. Analogue Immune Agents
    • Prescriber and Nonprescriber Profiles
      • Differences Between Prescriber and Nonprescriber Profiles
    • Cosentyx Awareness and Perceptions
      • Unaided and Aided Awareness of Cosentyx
        • Aided Awareness of and Familiarity with Cosentyx
        • Awareness of Cosentyx
        • Familiarity with Cosentyx
      • Familiarity with Cosentyx
        • Unaided Awareness of Drugs Currently Available for PsO
      • Sources of Familiarity with Cosentyx
        • Initial Reaction to and Interest in Cosentyx
          • Cosentyx Product Profile
          • Initial Reaction to Cosentyx After Viewing Product Profile
          • Initial Reaction to Cosentyx Based on Attributes
          • Initial Reaction to Cosentyx Based on the Following Attributes
          • Interest Level in Cosentyx
          • Physician Interest in Learning More About Cosentyx
        • Impressions of Cosentyx
          • Uniqueness of Cosentyx vs. Available PsO Agents
          • Physician-Rated Uniqueness of Cosentyx Compared with Other Available PsO Agents
          • Advantages of Cosentyxu2026In Their Own Words
          • Disadvantages of Cosentyxu2026In Their Own Words
          • Physician-Rated Risk-Benefit Ratio of Cosentyx
      • Cosentyx Trial and Use
        • Willingness to Prescribe Cosentyx
          • Physician Willingness to Prescribe Cosentyx
          • Physician-Rated Willingness to Prescribe Cosentyx
        • Number of Patients Currently Receiving Cosentyx
          • Cosentyx Patient Origination Among Prescribers
          • Origination of Patients Treated with Cosentyx
        • Anticipated Cosentyx Use
          • Candidates for Cosentyx by PsO Disease Severity
          • Candidates for Cosentyx by Treatment History
          • Cosentyx Candidates According to Nonprescribersu2026In Their Own Words
          • Cosentyx Line of Therapy
          • Cosentyx Line of Therapy if Price Were Not an Issue
        • Cosentyx Performance on Key Attributes
          • Prescribing Barriers Among Nonprescribersu2026In Their Own Words
          • Cosentyx Efficacyu2026In Their Own Words
          • Cosentyx Safetyu2026In Their Own Words
          • Overall Satisfaction with Cosentyx: Prescribers
          • Why high satisfaction (8-10)? (n = 44)
          • Physician-Rated Satisfaction with Cosentyx
          • Prescriber Satisfactionu2026In Their Own Words
          • Prescribing Barriers Among Cosentyx Prescribersu2026In Their Own Words
      • Effectiveness of Face-to-Face Detailing for Cosentyx
        • Cosentyx Sales Representative Frequency and Reach
          • Frequency of Dermatologist Contact with Cosentyx Representative
          • Dermatologistsu2019 Receipt of Patient Education Materials/Samples
          • Dermatologistsu2019 Use of Received Samples with PsO Patients
        • Satisfaction with Cosentyx Sales Representative
          • Cosentyx Sales Representative Performanceu2026In Their Own Words
        • Cosentyx Message Recall
          • Suggested Patient Types for Cosentyx
          • Dermatologists Provided Suggestions on Patient Types for Cosentyx
      • Appendix
        • Primary Market Research
          • Years in Practice
          • Regional Distribution of Dermatologists
          • Practice Type
          • Practice Location
          • Mean Number of PsO Patients
        • Additional Information
          • Preferred Biologics or Novel Oral Agents for Each Line
          • Prescription Drug Treatment by PsO Disease Severity
          • Opinions and Advice on Cosentyx for the Treatment of PsO*
          • Mean Number of Cosentyx Patient Inquiries per Physician
          • Result of Specific Patient Requests for Cosentyx
          • Physician-Rated Managed Care Approval Process for Cosentyx
          • Definition and Types of Psoriasis
          • Prevalence, Characteristics, and Treatment
          • Biologics/Small Molecules Approved for Psoriasis
          • Psoriasis Market News
          • Study Objectives
          • Dermatologistsu2019 Awareness of Products in Development for PsO
          • Administered Dosage to Patients Who Received Cosentyx
          • Advice for Novartisu2026In Their Own Words
          • Dermatologists define PsO severity by BSA score and patientsu2019 QOL.
          • Physicians Enrolling Patients into Cosentyxu2019s QuickStart Program
          • Prescribersu2019 Experience with Cosentyx Managed Care Requirements
          • Requirement for Managed Care Approval of Cosentyx Prescriptions
          • Products Currently in Clinical Trials or Under FDA Review for PsO Treatment
          • PsO Treatment Algorithmu2026In Their Own Words
          • Brand Share of Biologics or Novel Oral Agents Used in PsO
          • Cosentyx Dosingu2026In Their Own Words
          • Cosentyx Managed Care Approval Processu2026In Their Own Words
          • Dermatologistsu2019 Familiarity with Products in Development
          • Experience with Cosentyxu2019s QuickStart Program
          • Cosentyx Patient Supportu2026In Their Own Words
          • Dermatologistsu2019 Familiarity with Products in Development
          • Phototherapy Treatment by PsO Disease Severity
          • Patient Response to Biologics or Otezla
          • Percentage of Patients Starting on Each Biologic/Otezla in the Past Year Who Received It as a First-Line Systemic Therapy
          • PsO Products in Developmentu2026In Their Own Words
          • Percentage of Patients Who Discontinue on Treatment of Each Biologic/Otezla
          • Cosentyx Prescribers
          • Patients Still on Cosentyx
          • Patients Discontinued Cosentyx
          • Efficacy Attributesu2019 Importance When Choosing a Biologic Agent
          • Biologics/Novel Oral Agents Discussed by Representatives
          • Safety/Tolerability Attributesu2019 Importance When Choosing a Biologic
          • Pharmacology Attributesu2019 Importance When Choosing a Biologic
          • Importance of Patient Benefit-Related Attributes When Choosing a Biologic
          • Importance of Physician Benefit-Related Attributes When Choosing a Biologic
          • Statement Agreement
          • Statement Agreement

    launch Related Market Assessment Reports